3600 — Modern Dental Group Limited

Modern Dental Group Limited (3600.HK) — deep-value analysis

Reference price … (close 08/24/2026) · 934.214 mil. shares · market cap … · enterprise value … · single currency HKD (reporting and price) — no conversion issue.

Identification note. The ticker “3600” without a suffix doesn’t resolve on Yahoo and has no CIK at the SEC (Cayman/Hong Kong issuer, IFRS, reports on HKEX). Today’s first run produced a completely empty data pack for exactly this reason. This report’s primary source is not EDGAR but HKEXnews filings downloaded directly: Annual Report 2025 (04/23/2026), Annual Report 2024, Interim Report 2025 (09/17/2025), Interim Report 2024, plus 12 announcements from 2025-2026.

Corrections to the research brief. The brief (claude-sonnet-5, 09:02) contains four errors I verified against the source: (1) the price of … and the market cap of … are an old Stockopedia snapshot — today’s price is … and the market cap 7.87 bn, and the real P/E is 13.2x, not 9.39x; (2) the founding family is not “Ngai” but Chan — the founder is Chan Kwun Pan (68, founded Modern Dental Laboratory in August 1986), and the control vehicle is Triera Holdings, wholly owned by four Chan family members; the Ngai family was a historical co-shareholder and has fully exited; (3) the Hillhouse transaction was notified to the board on January 19, 2026 (not January 26 — that’s the price-reaction day), 161,163,302 shares (17.24%) at ~… sold by Ngai Shing Kin and Ngai Chi Ho Alwin through Prosperity Worldwide and NCHA Holdings (note 4, Directors’ Report, AR2025 p.44); (4) the Hexa Ceram acquisition was signed on 11/21/2024 and completed in January 2025, not “November 2024” as the GBL scorecard stated. The rest of the brief’s figures (S1 2026 profit alert, Q1 2026, FY2025) checked out exactly against the primary source.

Executive summary (1 page: thesis, estimated value, verdict)

Modern Dental Group is the largest independent global manufacturer of custom-made dental prosthetics — crowns, bridges, dentures, mouthguards, anti-snoring devices and aligners — built by systematically buying local dental labs in Western Europe, North America and Australia and moving physical production into its own factories in mainland China, Vietnam and Thailand. The model is a cost arbitrage masked by local brands: the client in Paris orders from Labocast, the one in Rotterdam from Permadental, the one in California from MicroDental, while the tooth is milled in Shenzhen or Hanoi. In 2025 the group delivered 2,851,083 cases, billed … with a gross margin of 55.8% and produced … net profit — records on all three lines (AR2025, MD&A p.6).

The investment thesis has three legs. First: digitalization works for the lab, not against it. Intraoral scanners don’t eliminate the lab; they eliminate the physical impression and its transport — the digital case reaches the Asian factory instantly, with fewer errors and shorter turnaround. Digital cases grew 32.7% in 2025 (1,039,188) and 24.6% in Q1 2026 (294,712), while total volume grew only 4.0%. This mix is the real source of margin expansion: gross margin rose from 48.9% (2022) to 53.5% (2024) and 55.8% (2025), reaching 56.8% in H2 2025. Second: the consolidation of a fragmented industry. There are over 5,500 dental labs in the US, and the largest players together hold under 15% of the market; scale and digitalization capital are exactly what family labs lack. Third: the balance sheet is clean and cash flow is real. Bank debt fell from … to … in one year, the net position is cash (… excluding leases), and CFO has exceeded net profit in each of the last four years (ratio 1.17-1.43x).

The counter-thesis is just as concrete. Of the … of revenue growth in 2025, … (64%) comes from Hexa Ceram and Digital Sleep — organic growth was only 4.0%. The two large markets that aren’t performing are also the most profitable long-term: North America fell 7.4% in local currency (MicroDental …), and Greater China 7.1% (mainland China …, Hong Kong …). Of the … increase in gross operating profit, … (21%) is a simple FX swing (currency gains of … in 2025 versus losses of … in 2024), and … is the absence of 2024’s one-off costs. And — most important for the valuation — 2025 capex was …, less than half of what was spent in any of the prior three years and 27% below actual depreciation of fixed assets (…). The reported free cash flow of … is inflated by an investment pause that cannot repeat indefinitely.

Estimated value. The flow definition I use in the valuation is normalized FCFE: CFO minus capex normalized to … minus bank interest (…), lease interest (…), lease principal (…) and dividends to minorities (…) — …, versus … on the simple CFO−capex definition (divergence …, so above the 10% threshold that requires FCFE). Triangulating five models gives a wide and honest range: from … (Greenwald no-growth earnings power value) to … (optimistic DCF), with a median of … (own historical multiples) and a Monte Carlo across 20,000 scenarios with a median of … and a …% probability of undervaluation. Intrinsic value range: … — … per share, centered on … — …

Verdict: PARTIAL BUY, SMALL POSITION, ON WEAKNESS. The business is better than I expected before opening the filings — return on invested capital excluding goodwill of 33%, net-cash balance sheet, real contrarian buybacks. But the price of … is at 13.2x last year’s profit and …x the estimated 2026 profit, i.e. above everything the market has paid for this stock over the last five years (6.6-10.2x at average annual price). The stock rose 66% in 12 months and 11.9% in a single day (08/14/2026, after the profit alert on 08/13). Half-year results are published on August 27, three days after this report, and the profit alert is already priced in. The zone where the margin of safety becomes real again is below … (where EPV and historical multiples stop saying “expensive”), and it becomes compelling below … I won’t force an entry at an all-time high for a company whose organic growth was 4%.